These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 15143880)

  • 21. Adjuvant chemotherapy with gemcitabine for patients with resectable pancreatic cancer.
    Maisonneuve P; Lowenfels AB
    JAMA; 2007 Jun; 297(23):2581; author reply 2582. PubMed ID: 17579223
    [No Abstract]   [Full Text] [Related]  

  • 22. [Radiochemotherapy with gemcitabine and cisplatin in pancreatic cancer -- feasible and effective].
    Wilkowski R; Thoma M; Heinemann V; Rau HG; Wagner A; Stoffregen C; Dühmke E
    Strahlenther Onkol; 2003 Feb; 179(2):78-86. PubMed ID: 12590317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer.
    Park JK; Ryu JK; Lee JK; Yoon WJ; Lee SH; Kim YT; Yoon YB
    Pancreas; 2006 Nov; 33(4):397-402. PubMed ID: 17079946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study.
    Van Laethem JL; Hammel P; Mornex F; Azria D; Van Tienhoven G; Vergauwe P; Peeters M; Polus M; Praet M; Mauer M; Collette L; Budach V; Lutz M; Van Cutsem E; Haustermans K
    J Clin Oncol; 2010 Oct; 28(29):4450-6. PubMed ID: 20837948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liver perfusion chemotherapy with 5-Fluorouracil followed by systemic gemcitabine administration for resected pancreatic cancer: preliminary results of a prospective phase 2 study.
    Kurosaki I; Kawachi Y; Nihei K; Tsuchiya Y; Aono T; Yokoyama N; Shimizu T; Hatakeyama K
    Pancreas; 2009 Mar; 38(2):161-7. PubMed ID: 18797423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regional chemotherapy in locally advanced pancreatic cancer: RECLAP trial.
    Davis JL; Pandalai P; Ripley RT; Langan RC; Steinberg SM; Walker M; Toomey MA; Levy E; Avital I
    Trials; 2011 May; 12():129. PubMed ID: 21595953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resected Pancreatic Cancer With N2 Node Involvement Is Refractory to Gemcitabine-Based Adjuvant Chemotherapy.
    Liu C; Cheng H; Jin K; Fan Z; Gong Y; Qian Y; Deng S; Huang Q; Ni Q; Yu X; Luo G
    Cancer Control; 2020; 27(1):1073274820915947. PubMed ID: 32268796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma.
    Cantore M; Serio G; Pederzoli P; Mambrini A; Iacono C; Pulica C; Capelli P; Lombardi M; Torri T; Pacetti P; Pagani M; Fiorentini G
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):504-8. PubMed ID: 16633830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone.
    McDonald AM; Dulaney CR; López-Araujo J; Posey JA; Keene KS; Christein JD; Heslin MJ; Wood TE; Jacob R
    J Gastrointest Cancer; 2015 Jun; 46(2):149-55. PubMed ID: 25782589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
    Li Y; Sun J; Jiang Z; Zhang L; Liu G
    J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506.
    Ishii H; Furuse J; Boku N; Okusaka T; Ikeda M; Ohkawa S; Fukutomi A; Hamamoto Y; Nakamura K; Fukuda H;
    Jpn J Clin Oncol; 2010 Jun; 40(6):573-9. PubMed ID: 20185458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial.
    Small W; Berlin J; Freedman GM; Lawrence T; Talamonti MS; Mulcahy MF; Chakravarthy AB; Konski AA; Zalupski MM; Philip PA; Kinsella TJ; Merchant NB; Hoffman JP; Benson AB; Nicol S; Xu RM; Gill JF; McGinn CJ
    J Clin Oncol; 2008 Feb; 26(6):942-7. PubMed ID: 18281668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The age-adjusted Charlson comorbidity index is an independent prognostic factor in pancreatic cancer patients who receive curative resection followed by adjuvant chemotherapy.
    Aoyama T; Yamamoto N; Kamiya M; Murakawa M; Tamagawa H; Sawazaki S; Numata M; Kobayashi S; Ueno M; Morimoto M; Shiozawa M; Yukawa N; Oshima T; Yoshikawa T; Rino Y; Masuda M; Morinaga S
    J Cancer Res Ther; 2020 Dec; 16(Supplement):S116-S121. PubMed ID: 33380664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gemcitabine therapy in patients with advanced pancreatic cancer.
    Min YJ; Joo KR; Park NH; Yun TK; Nah YW; Nam CW; Park JH
    Korean J Intern Med; 2002 Dec; 17(4):259-62. PubMed ID: 12647642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine.
    Baschnagel A; Shah C; Margolis J; Nadeau L; Stein J; Jury R; Robertson JM
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e331-5. PubMed ID: 22420967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.
    Xie H; Lin J; Thomas DG; Jiang W; Liu X
    Int J Clin Exp Pathol; 2012; 5(4):347-55. PubMed ID: 22670179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection.
    Berriochoa CA; Abdel-Wahab M; Leyrer CM; Khorana A; Matthew Walsh R; Kumar AMS
    J Dig Dis; 2017 Nov; 18(11):642-649. PubMed ID: 29055078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP).
    Fensterer H; Schade-Brittinger C; Müller HH; Tebbe S; Fass J; Lindig U; Settmacher U; Schmidt WE; Märten A; Ebert MP; Kornmann M; Hofheinz R; Endlicher E; Brendel C; Barth PJ; Bartsch DK; Michl P; Gress TM;
    Ann Oncol; 2013 Oct; 24(10):2576-2581. PubMed ID: 23897705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer.
    Lee KH; Chie EK; Im SA; Kim JH; Kwon J; Han SW; Oh DY; Jang JY; Kim JS; Kim TY; Bang YJ; Kim SW; Ha SW
    Cancer Res Treat; 2021 Oct; 53(4):1096-1103. PubMed ID: 33421976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant chemotherapy with gemcitabine for patients with resectable pancreatic cancer.
    Shivnani AT
    JAMA; 2007 Jun; 297(23):2581-2; author reply 2582. PubMed ID: 17579222
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.